In the BioHarmony Drug Report Database

"Preview" Icon

Darolutamide

Nubeqa (darolutamide) is a small molecule pharmaceutical. Darolutamide was first approved as Nubeqa on 2019-07-30. It has been approved in Europe to treat castration-resistant prostatic neoplasms. The pharmaceutical is active against androgen receptor. Nubeqa’s patent is valid until 2036-01-28 (FDA).

 

Trade Name

 

Nubeqa
 

Common Name

 

darolutamide
 

ChEMBL ID

 

CHEMBL4297185
 

Indication

 

castration-resistant prostatic neoplasms
 

Drug Class

 

Non-steroid antiandrogens

Image (chem structure or protein)

Darolutamide structure rendering